Abeta 42 lowering agents

Abstract

The invention provides a method of preventing, delaying, or reversing the progression of Alzheimer's disease by administering an Aβ42 lowering agent to a mammal under conditions in which levels of Aβ42 are selectively reduced, levels of Aβ38 are increased, and levels of Aβ40 are unchanged. The invention provides methods and materials for developing and identifying Aβ42 lowering agents. In addition, the invention provides methods for identifying agents that increase the risk of developing, or hasten progression of, Alzheimer's disease. The invention also provides compositions of Aβ42 lowering agents and antioxidants, Aβ42 lowering agents and non-selective secretase inhibitors, as well as Aβ42 lowering agents and acetylcholinesterase inhibitors. The invention also provides kits containing Aβ42 lowering agents, antioxidants, non-selective secretase inhibitors, and/or acetylcholinesterase inhibitors as well as instructions related to dose regimens for Aβ42 lowering agents, antioxidants, non-selective secretase inhibitors, and acetylcholinesterase inhibitors.

Dependencies are inferred from the claim text.